Last edition
News about "Phase III study"
MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1RA MDR-001 in China
MindRank has initiated its Phase III MOBILE trial of MDR-001, an AI-designed oral GLP-1 receptor agonist, evaluating long-term efficacy and safety in 750 obesity and type 2 diabetes patients in China.
Phase III Study | 02/03/2026 | By News Bureau | 206
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Phase III Study | 15/01/2026 | By News Bureau | 121
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy